Proliant Health & Biologicals Launches AlbufreeDX: A New Era for Albumin with Animal-Free Recombinant Human Albumin

Proliant Health & Biologicals Sets New Standards with AlbufreeDX

Proliant Health & Biologicals, a leading global provider of purified proteins, has recently introduced AlbufreeDX, a revolutionary recombinant human albumin (rHA) developed to cater to the increasing need for high-performance, animal-free ingredients tailored for applications in diagnostics and biosciences. With over two decades of expertise in manufacturing albumin and other purified proteins, Proliant ensures consistent quality and reliable supply on a worldwide scale. The company is headquartered in Ankeny, Iowa, and has production facilities in the United States and New Zealand. They are continuously expanding their capacity to support the growing markets in biotechnology, diagnostics, and healthcare.

Albumin plays a vital role in diagnostics, biopharmaceutical manufacturing, and research processes due to its ability to stabilize proteins, prevent unwanted surface binding, and enhance the performance and reproducibility of assays. As diagnostic tests evolve toward new analytes, greater sensitivity, and higher throughput platforms, the raw materials must exhibit exceptional consistency and purity to avoid fluctuations and signal disturbances. Traditional albumins derived from animal or human sources may entail additional testing requirements, a higher demand for traceability, and more complex regulatory oversight.

Dr. Christopher Warner, Vice President of Research and Development, states, "IVD companies are focusing on products that are free from animal and human components to simplify regulatory complexity across regions. AlbufreeDX supports this strategy by streamlining global and IVDR compliance while simultaneously aiding companies in fulfilling their ESG commitments."

Produced through precision fermentation, AlbufreeDX is characterized by its high purity, reliable performance, and excellent batch-to-batch reproducibility. It is especially suitable for applications such as protein stabilization, surface blocking, reagent formulation, and reference standards—particularly where minimizing variability and avoiding the risk of animal-borne pathogens is essential.

As Dr. Christopher Detzel, President and CEO, remarks, "As customer requirements have evolved, so has our portfolio. AlbufreeDX is a natural extension of our strengths; we are offering an animal-free albumin alternative while ensuring the consistency, reliability, and scalability that our customers expect."

The launch of AlbufreeDX reinforces Proliant's expanding life science portfolio. Upcoming products will include AlbufreeTX for cell culture and AlbufreeCGT to support new workflows in cell and gene therapy.

For more information, visit our website or contact us at the media relations email provided.

AlbufreeDX signifies an important breakthrough in the biotechnology sector, potentially transforming how researchers and manufacturers address their albumin needs. By prioritizing animal-free resources, Proliant Health & Biologicals is not only advancing the scientific community's capabilities but also responding to increasing ethical demands in the industry. This development sets a precedent for future innovations in the field and exemplifies the company's commitment to quality and sustainability.